{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '530 Seventh Avenue',
 'address2': 'Suite 2201',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 59.8,
 'askSize': 800,
 'averageDailyVolume10Day': 78337,
 'averageVolume': 213047,
 'averageVolume10days': 78337,
 'beta': None,
 'beta3Year': None,
 'bid': 19,
 'bidSize': 1100,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 41.28,
 'dayLow': 39.01,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -27.989,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1522438144,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 45.343143,
 'fiftyTwoWeekHigh': 59.32,
 'fiftyTwoWeekLow': 22,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14727773,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 64,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.24434,
 'heldPercentInstitutions': 0.29,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/zentalis.com',
 'longBusinessSummary': 'Zentalis Pharmaceuticals, LLC, a clinical-stage '
                        'biopharmaceutical company, focuses on discovering and '
                        'developing small molecule therapeutics targeting '
                        'fundamental biological pathways of cancers in the '
                        'United States. Its lead product candidate is the '
                        'ZN-c5, an oral selective estrogen receptor degrader '
                        'that is in a Phase I/II clinical trial for the '
                        'treatment of breast cancer. The company is also '
                        'developing ZN-c3, an inhibitor of WEE1, a protein '
                        'tyrosine kinase, which is in Phase I/II clinical '
                        'trial for the treatment of advanced solid tumors; '
                        'ZN-d5, a selective inhibitor of B-cell lymphoma 2 for '
                        'the treatment of hematological malignancies; and '
                        'ZN-e4, an irreversible inhibitor of mutant epidermal '
                        'growth factor receptor that is in Phase I/II clinical '
                        'trial for the treatment of advanced non-small cell '
                        'lung cancer. Zentalis Pharmaceuticals, LLC was '
                        'founded in 2014 and is based in New York, New York.',
 'longName': 'Zentalis Pharmaceuticals, LLC',
 'market': 'us_market',
 'marketCap': 1421147392,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_647536411',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -54161000,
 'nextFiscalYearEnd': 1640908800,
 'open': 40.79,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '212 433 3791',
 'previousClose': 40.86,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 41.28,
 'regularMarketDayLow': 39.01,
 'regularMarketOpen': 40.79,
 'regularMarketPreviousClose': 40.86,
 'regularMarketPrice': 40.79,
 'regularMarketVolume': 139131,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 35878500,
 'sharesPercentSharesOut': 0.0678,
 'sharesShort': 2431055,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1320668,
 'shortName': 'Zentalis Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.2132,
 'shortRatio': 7.67,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'ZNTL',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 39.211796,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '39a4bee6-8ddb-3930-b936-d5bcf9eb8cf7',
 'volume': 139131,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.zentalis.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10018'}